Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs

Kevin Koo, Ronald L. Yap

Research output: Contribution to journalArticle

Abstract

Introduction The purpose of this study is to characterize contemporary trends in direct-to-consumer advertising of urological pharmaceutical products on American prime-time television programs. Television is the highest expenditure segment of the consumer drug marketing industry. The extent of advertising in urology and its potential impact on patients are not well understood. Methods We retrospectively analyzed an indexed database of prime-time news broadcasts on 5 national networks in the United States. The database was queried with the names of 77 urological pharmaceutical products to identify all commercials that aired during a 36-month period between 2010 and 2013. Noncommercial segments were excluded. Descriptive and linear regression analysis was performed. Results We analyzed 4,574 broadcasts, representing 3,067.5 hours of prime-time television. A total of 2,068 commercials for 8 products and 4 urological indications were aired, including sildenafil and tadalafil for erectile dysfunction; 2 testosterone products for hypogonadism; fesoterodine, oxybutynin and solifenacin for overactive bladder; and sipuleucel-T for metastatic castration resistant prostate cancer. Commercials for male oriented indications accounted for 90% of the sample. At least 1 urological advertisement was contained in 1,744 broadcasts (38%). The introduction of television marketing for newly approved testosterone supplementation products in 2012 corresponded to strongly linear growth in overall urological advertising, reaching peak levels in 2013. Conclusions Urological pharmaceutical products have been consistently advertised on television. Commercials have extensively targeted male oriented indications. Viewers of national news programs were exposed to urological advertising during about 40% of broadcasts with steadily increasing exposure since 2012. Providers should be aware of these trends to contextualize demand and monitor prescribing patterns.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalUrology Practice
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Television
Marketing
Testosterone
Pharmaceutical Preparations
Databases
Overactive Urinary Bladder
Hypogonadism
Castration
Drug Industry
Urology
Erectile Dysfunction
Health Expenditures
Names
Linear Models
Prostatic Neoplasms
Regression Analysis
Direct-to-Consumer Advertising
Growth

Keywords

  • direct-to-consumer advertising
  • drug industry
  • television
  • testosterone
  • urological agents

ASJC Scopus subject areas

  • Urology

Cite this

Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs. / Koo, Kevin; Yap, Ronald L.

In: Urology Practice, Vol. 4, No. 1, 01.01.2017, p. 7-13.

Research output: Contribution to journalArticle

@article{15a12960d4fd4ebf9ea4bbec457a413e,
title = "Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs",
abstract = "Introduction The purpose of this study is to characterize contemporary trends in direct-to-consumer advertising of urological pharmaceutical products on American prime-time television programs. Television is the highest expenditure segment of the consumer drug marketing industry. The extent of advertising in urology and its potential impact on patients are not well understood. Methods We retrospectively analyzed an indexed database of prime-time news broadcasts on 5 national networks in the United States. The database was queried with the names of 77 urological pharmaceutical products to identify all commercials that aired during a 36-month period between 2010 and 2013. Noncommercial segments were excluded. Descriptive and linear regression analysis was performed. Results We analyzed 4,574 broadcasts, representing 3,067.5 hours of prime-time television. A total of 2,068 commercials for 8 products and 4 urological indications were aired, including sildenafil and tadalafil for erectile dysfunction; 2 testosterone products for hypogonadism; fesoterodine, oxybutynin and solifenacin for overactive bladder; and sipuleucel-T for metastatic castration resistant prostate cancer. Commercials for male oriented indications accounted for 90{\%} of the sample. At least 1 urological advertisement was contained in 1,744 broadcasts (38{\%}). The introduction of television marketing for newly approved testosterone supplementation products in 2012 corresponded to strongly linear growth in overall urological advertising, reaching peak levels in 2013. Conclusions Urological pharmaceutical products have been consistently advertised on television. Commercials have extensively targeted male oriented indications. Viewers of national news programs were exposed to urological advertising during about 40{\%} of broadcasts with steadily increasing exposure since 2012. Providers should be aware of these trends to contextualize demand and monitor prescribing patterns.",
keywords = "direct-to-consumer advertising, drug industry, television, testosterone, urological agents",
author = "Kevin Koo and Yap, {Ronald L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.urpr.2016.03.005",
language = "English (US)",
volume = "4",
pages = "7--13",
journal = "Urology Practice",
issn = "2352-0779",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs

AU - Koo, Kevin

AU - Yap, Ronald L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction The purpose of this study is to characterize contemporary trends in direct-to-consumer advertising of urological pharmaceutical products on American prime-time television programs. Television is the highest expenditure segment of the consumer drug marketing industry. The extent of advertising in urology and its potential impact on patients are not well understood. Methods We retrospectively analyzed an indexed database of prime-time news broadcasts on 5 national networks in the United States. The database was queried with the names of 77 urological pharmaceutical products to identify all commercials that aired during a 36-month period between 2010 and 2013. Noncommercial segments were excluded. Descriptive and linear regression analysis was performed. Results We analyzed 4,574 broadcasts, representing 3,067.5 hours of prime-time television. A total of 2,068 commercials for 8 products and 4 urological indications were aired, including sildenafil and tadalafil for erectile dysfunction; 2 testosterone products for hypogonadism; fesoterodine, oxybutynin and solifenacin for overactive bladder; and sipuleucel-T for metastatic castration resistant prostate cancer. Commercials for male oriented indications accounted for 90% of the sample. At least 1 urological advertisement was contained in 1,744 broadcasts (38%). The introduction of television marketing for newly approved testosterone supplementation products in 2012 corresponded to strongly linear growth in overall urological advertising, reaching peak levels in 2013. Conclusions Urological pharmaceutical products have been consistently advertised on television. Commercials have extensively targeted male oriented indications. Viewers of national news programs were exposed to urological advertising during about 40% of broadcasts with steadily increasing exposure since 2012. Providers should be aware of these trends to contextualize demand and monitor prescribing patterns.

AB - Introduction The purpose of this study is to characterize contemporary trends in direct-to-consumer advertising of urological pharmaceutical products on American prime-time television programs. Television is the highest expenditure segment of the consumer drug marketing industry. The extent of advertising in urology and its potential impact on patients are not well understood. Methods We retrospectively analyzed an indexed database of prime-time news broadcasts on 5 national networks in the United States. The database was queried with the names of 77 urological pharmaceutical products to identify all commercials that aired during a 36-month period between 2010 and 2013. Noncommercial segments were excluded. Descriptive and linear regression analysis was performed. Results We analyzed 4,574 broadcasts, representing 3,067.5 hours of prime-time television. A total of 2,068 commercials for 8 products and 4 urological indications were aired, including sildenafil and tadalafil for erectile dysfunction; 2 testosterone products for hypogonadism; fesoterodine, oxybutynin and solifenacin for overactive bladder; and sipuleucel-T for metastatic castration resistant prostate cancer. Commercials for male oriented indications accounted for 90% of the sample. At least 1 urological advertisement was contained in 1,744 broadcasts (38%). The introduction of television marketing for newly approved testosterone supplementation products in 2012 corresponded to strongly linear growth in overall urological advertising, reaching peak levels in 2013. Conclusions Urological pharmaceutical products have been consistently advertised on television. Commercials have extensively targeted male oriented indications. Viewers of national news programs were exposed to urological advertising during about 40% of broadcasts with steadily increasing exposure since 2012. Providers should be aware of these trends to contextualize demand and monitor prescribing patterns.

KW - direct-to-consumer advertising

KW - drug industry

KW - television

KW - testosterone

KW - urological agents

UR - http://www.scopus.com/inward/record.url?scp=85007349026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007349026&partnerID=8YFLogxK

U2 - 10.1016/j.urpr.2016.03.005

DO - 10.1016/j.urpr.2016.03.005

M3 - Article

VL - 4

SP - 7

EP - 13

JO - Urology Practice

JF - Urology Practice

SN - 2352-0779

IS - 1

ER -